Data Insights

KITE-363 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

KITE-363 by Gilead Sciences for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

KITE-363 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Chronic Lymphocytic Leukemia (CLL)

Data Insights

KITE-363 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Mantle Cell Lymphoma

Data Insights

KITE-363 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Burkitt Lymphoma

Data Insights

KITE-363 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

KITE-363 by Gilead Sciences for Refractory Acute Myeloid Leukemia: Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Refractory Acute Myeloid Leukemia

Data Insights

KITE-363 by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Primary Mediastinal B-Cell Lymphoma

Data Insights

KITE-363 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Diffuse Large B-Cell Lymphoma